UK Crispr And Cas Genes Market Size & Outlook, 2024-2030
UK crispr and cas genes market, 2018-2030 (US$M)
Related Markets
UK crispr and cas genes market highlights
- The UK crispr and cas genes market generated a revenue of USD 268.7 million in 2024 and is expected to reach USD 688.9 million by 2030.
- The UK market is expected to grow at a CAGR of 17.4% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Crispr and cas genes market data book summary
| Market revenue in 2024 | USD 268.7 million |
| Market revenue in 2030 | USD 688.9 million |
| Growth rate | 17.4% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, UK accounted for 5.7% of the global crispr and cas genes market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany crispr and cas genes market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 688.9 million by 2030.
Product was the largest segment with a revenue share of 89.06% in 2024. Horizon Databook has segmented the UK crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
In February 2016, the UK became the first country to allow genetic modifications in the embryo, along with permitting the legal replacement of embryonic genes with a third person’s genes. The permissions and grants to improve the research in gene editing are expected to propel growth for CRISPR technology in the UK.
However, the safety of gene editing remains a challenge. For instance, some national agencies have stated that genome editing could be used to cause an outbreak of a dangerous disease. Silence Therapeutics, a UK based company, is taking up projects to implement CRISPR to add genes to mice for protein production.
In January 2019, Horizon Discovery, a UK company, received the license to develop a CRISPR-based gene-editing tool from the U.S.-based Rutgers University. In January 2020, the company collaborated with U.S.-based Mammoth Biosciences to access the latter’s CRISPR platform for development of next-generation engineered CHO cell lines.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK crispr and cas genes market size, by product & service, 2018-2030 (US$M)
UK CRISPR And Cas Genes Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
